INTRODUCTION {#s1}
============

Reduced intensity conditioning (RIC) regimens have been developed with aim to extend the use of allogeneic hematopoietic stem cell therapy (allo-SCT) to older patients and those with pre-existing comorbidities \[[@R1]\]. According to data from Center for International Blood and Marrow Transplant Research (CIBMTR) and European Society for Blood and Marrow Transplantation (EBMT), the number of such procedures is steadily increasing, reaching currently 40% of all allo-SCT \[[@R2],[@R3]\]. Nowadays, peripheral blood (PB) is the predominant graft source for adult allogeneic donor transplants (almost 80%) \[[@R2]--[@R4]\]. Compared to myeloablative (MAC) setting, in the RIC procedures the curative potential relies principally on the immunological effects of the graft against the leukemia the so called GVL effect rather than on the power of chemo- or radiotherapy \[[@R1]\]. Thus, cellular composition of grafts is believed to be a significant determinant of outcome. Nevertheless, the impact of PB stem cell grafts cellularity on the outcome of RIC allo-SCT is still controversial. This is mainly due to the fact that inconsistent results have been reported regarding the influence of CD3+ and CD34+ cell doses on the incidence of graft-*versus*-host disease (GVHD), disease control and survival in the studies published so far \[[@R5]--[@R13]\]. These discrepancies may be at least in part explained by the differences in disease categories, disease status at transplant, donor type and the degree of HLA match between donor and recipient. Furthermore, the role of CD3+ cell counts is less well characterized than that of CD34+ and was previously a part of only one report regarding unrelated donor non-myeloablative allo-SCT \[[@R13]\]. In the current retrospective EBMT registry study we aimed to analyze the impact of CD3+ and CD34+ cell doses in PBSC grafts on the outcome of RIC allo-SCT in a homogeneous population of patients, taking into account aforementioned factors. We focused on the population of patients with AML allografted in first complete remission (CR1) from fully matched (10/10 match) unrelated donors (MUD) after year 2000.

RESULTS {#s2}
=======

Two hundred and three patients were enrolled. Their median age was 58 (range, 21-73). Detailed patient and transplant characteristics are summarized in (Table [1](#T1){ref-type="table"}).

###### Patient characteristics

  --------------------------------------------------------- ------------------
  N                                                         203
  Patient sex                                               
   Male                                                     116 (57%)
   Female                                                   87 (43%)
  Median patient age, years (range)                         58 (21-73)
  AML cytogenetic risk                                      
   Favorable                                                4 (2%)
   Intermediate                                             142 (70%)
   Adverse                                                  42 (21%)
   Failed                                                   15 (7%)
  Number of induction courses to achieve CR1                
   1                                                        133 (66%)
   \>1                                                      70 (34%)
  Interval from diagnosis to achieve CR1, days (range)      51 (21-350)
  Interval from CR1 to transplantation, days (range)        115 (15-351)
  Median donor age, years (range)                           34 (19-61)
  Donor sex                                                 
   Male                                                     135 (67%)
   Female                                                   68 (33%)
  Female donor to male recipient                            32 (16%)
  Patient CMV serosatus                                     
   Negative                                                 94 (46%)
   Positive                                                 109 (54%)
  Donor CMV serostatus                                      
   Negative                                                 134 (66%)
   Positive                                                 69 (34%)
  Conditioning                                              
   Chemotherapy-based                                       143 (70%)
    Fludarabine + busulfan                                  110
    Fludarabine + treosulfan                                14
    Fludarabine + melphalan                                 12
    Other                                                   7
   TBI-based                                                60 (30%)
  In-vivo T-cell depletion                                  166 (82%)
   ATG                                                      153
   Campath                                                  13
  GVHD prophylaxis                                          
   CsA + Mtx                                                129 (64%)
   CsA + MMF                                                69 (34%)
   Other                                                    5 (2%)
  Median CD34(+) dose, cells per kilogram x 10\^6 (range)   6.53 (1.34-41.3)
   Interquartile range                                      5.0-8.25
  Median CD3(+) dose, cells per kilogram x 10\^6 (range)    250 (50-885)
   Interquartile range                                      175.4-347
  Median year of transplantation, range                     2011 (2000-2012)
  Median follow-up, months (range)                          22 (3-105)
  --------------------------------------------------------- ------------------

Abbreviations: AML -- acute myeloid leukemia; CR1 -- first complete remission; CMV -- cytomegalovirus; TBI - total body irradiation; ATG - antithymocyte globulin; GVHD -- graft-versus-host disease; CsA -- cyclospirin A; Mtx -- methotrexate; MMF - mycophenolate mofetil

The probabilities of OS and LFS at 2 years from transplantation for the whole study group were 64% (95% CI : 56-71) and 60% (53-68), respectively. The relapse rate was 24% (18-30), whereas NRM 16% (11-22). The incidence of grade II-IV acute GVHD was 31% (25-38), whereas severe grade III-IV was 10% (6-14). Chronic GVHD rate was estimated at 44% (37-52).

Impact of graft content on the incidence of GVHD {#s2_1}
------------------------------------------------

In a univariate analysis, patients transplanted with the highest CD3+ doses (above the third quartile cut-off point value, \>347 × 10\^6/kg) had an increased incidence of acute GVHD grade II-IV (45% *vs*. 26%, *P* = .007) and grade III-IV (20% *vs*. 6%, *P* = .003), respectively (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). In the quartile of patients transplanted with the highest CD34+ graft content (\>8.25 × 10\^6 /kg) increased incidence of grade III-IV acute GVHD (18% *vs*. 7%, *P* = .02) was observed (Figure [3](#F3){ref-type="fig"}). Other risk factors for acute GVHD were transplantation from CMV seropositive donors (grade II-IV; 44% *vs*. 24%, *P* = .005) and from females to males (grade III-IV; 19% *vs*. 8%, *P* = .04). There was no association between cellular composition of grafts and the incidence of chronic GVHD. Use of in-vivo T-cell depletion was a protective factor for the presence of chronic GVHD (40% *vs*. 64%, *P* = .01).

![Impact of CD3+ dose on the incidence of acute GVHD grade II-IV (*P* = .007)](oncotarget-07-27255-g001){#F1}

![Impact of CD3+ dose on the incidence of acute GVHD grade III-IV (*P* = .003)](oncotarget-07-27255-g002){#F2}

In a multivariate analysis, CD3+ dose was the only adverse predicting factor for acute GVHD grade II-IV (HR= 2.1; 95%CI: 1.25-3.55, *P* = .005) and together with CD34+ dose for acute GVHD grade III-IV (CD3+, HR=3.6; 95%CI: 1.45-9.96, *P* = .006; CD34+, HR=2.65; 95%CI: 1.07-6.57, *P* = .04). Use of in-vivo T-cell depletion was an independent predictor for lower incidence of chronic GVHD (HR= 0.43; 95%CI: 0.25-0.73, *P* = .002). There was also no significant correlation between the number of CD3+ and CD34+ cells infused (Spearman correlation coefficient: *P* = .2). However, there was a trend towards more patients transplanted with the highest CD3+ cell numbers (\>347 × 10\^6/kg) in in the group of patients with CD34+ cell dose higher than 8.25 × 10\^6 /kg, *P* = .08.

![Impact of CD34+ dose on the incidence of acute GVHD grade III-IV (*P* = .02)](oncotarget-07-27255-g003){#F3}

Impact of graft content on the engraftment {#s2_2}
------------------------------------------

The engraftment rate equaled 99% and was not affected by CD3+ nor by the CD34+ counts. Only one patient did not engraft and one patient experienced a late graft failure. Kinetics of engraftment was not faster in patients given upper quartile CD3+ cell counts (17 days (1-18) *vs*. 17 (16-28), *P* = .93) nor in those that were given upper quartile CD34+ cell counts (18 (1-27) *vs*. 17 (6-28), *P* = .46). Likewise, the rates of full donor chimerism were not statistically higher in case of infusion of the highest CD3+ (86.8% *vs*. 79%, *P* = .28) nor CD34+ (84.2% *vs*. 79.8%, *P* = .55) cell doses.

Impact of graft content on the other transplantation outcome {#s2_3}
------------------------------------------------------------

There was no association between cellular composition of grafts and AML relapse, NRM and survival (both OS and LFS). Factors that independently affected unfavorable outcome were: time from diagnosis to CR1 above median for NRM, time from CR1 to allo-SCT below median and unfavorable karyotype for LFS and OS, and unfavorable karyotype for relapse incidence. Detailed results of univariate and multivariate analyses for significant factors are presented in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively.

###### Results of univariate analysis of factors affecting outcome

                                                                                               RI % at 2 years (95% CI)   NRM % at 2 years (95% CI)   LFS % at 2 years (95% CI)   OS % at 2 years (95% CI)   aGVHD II-IV % at 100 days (95% CI)   aGVHD III-IV % at 100 days (95% CI)   cGVHD % at 2 years (95% CI)
  ----------------------------------------------------------------------------- -------------- -------------------------- --------------------------- --------------------------- -------------------------- ------------------------------------ ------------------------------------- -----------------------------
  **CD34(+) dose -- quartiles** (cells per kg x 10\^6)                          1 (1.34-5.0)   21 (10-36)                 19 (8-32)                   60 (45-76)                  64 (49-79)                 30 (18-42)                           6 (2-15)                              48 (32-62)
  2 (5.0-6.53)                                                                  22 (11-35)     16 (6-29)                  62 (48-77)                  68 (54-82)                  36 (23-50)                 9 (3-19)                             42 (27-56)                            
  3 (6.53-8.25)                                                                 27 (14-42)     11 (4-22)                  62 (47-78)                  68 (53-83)                  29 (17-42)                 6 (2-15)                             38 (22-53)                            
  4 (8.25-41.3)                                                                 26 (14-39)     19 (9-33)                  54 (40-69)                  55 (40-70)                  30 (18-43)                 18 (9-30)                            46 (31-60)                            
  *P*-value                                                                     0.87           0.45                       0.67                        0.49                        0.79                       0.12                                 0.68                                  
  **CD34(+) dose \< \>3 quartile cut-off point value** (cells per kg x 10\^6)   \<8.25         23 (16-31)                 15 (9-22)                   62 (53-71)                  67 (58-75)                 31 (24-39)                           7 (4-12)                              43 (34-51)
  \>8.25                                                                        26 (14-39)     19 (13-27)                 54 (40-69)                  55 (40-70)                  30 (18-43)                 18 (9-30)                            46 (31-60)                            
  *P*-value                                                                     0.69           0.44                       0.24                        0.16                        0.84                       **0.02**                             0.79                                  
  **CD3(+) dose -- quartiles** (cells per kg x 10\^6)                           1 (50-175.4)   20 (10-33)                 16 (7-29)                   64 (49-78)                  70 (56-84)                 25 (14-38)                           6 (2-15)                              40 (25-55)
  2 (175.4-250)                                                                 28 (15-43)     16 (7-29)                  56 (41-71)                  65 (50-79)                  31 (18-44)                 6 (2-15)                             52 (36-66)                            
  3 (250-347)                                                                   32 (18-46)     12 (5-24)                  55 (40-71)                  57 (41-72)                  23 (12-36)                 6 (2-16)                             41 (26-55)                            
  4 (347-885)                                                                   15 (6-26)      21 (10-35)                 65 (50-79)                  64 (49-79)                  45 (31-59)                 20 (10-32)                           43 (28-58)                            
  *P*-value                                                                     0.27           0.67                       0.73                        0.60                        **0.04**                   **0.03**                             0.57                                  
  **CD3(+) dose \< \>3 quartile cut-off point value** (cells per kg x 10\^6)    \<347          27 (19-35)                 15 (9-21)                   59 (50-67)                  64 (55-72)                 26 (20-34)                           6 (3-11)                              44 (35-53)
  \>347                                                                         15 (7-26)      21 (14-28)                 65 (50-79)                  64 (49-79)                  45 (31-59)                 20 (10-32)                           43 (28-58)                            
  *P*-value                                                                     0.13           0.39                       0.53                        0.73                        **0.007**                  **0.003**                            0.88                                  
  **Interval from diagnosis to achieve CR1**                                    \<median       22 (14-32)                 10 (5-18)                   67 (57-77)                  68 (58-78)                 29 (21-39)                           8 (4-15)                              46 (34-56)
  \>median                                                                      23 (15-33)     23 (15-33)                 53 (42-64)                  60 (49-71)                  33 (24-43)                 11 (6-18)                            45 (34-55)                            
  *P*-value                                                                     0.93           **0.03**                   0.13                        0.23                        0.59                       0.49                                 0.86                                  
  **Interval from CR1 to transplantation**                                      \<median       27 (18-37)                 23 (14-33)                  50 (39-62)                  52 (41-63)                 32 (23-41)                           8 (4-15)                              42 (30-52)
  \>median                                                                      19 (11-28)     11 (6-19)                  70 (60-80)                  75 (66-85)                  30 (21-40)                 11 (6-18)                            49 (38-59)                            
  *P*-value                                                                     0.12           0.08                       **0.007**                   **0.001**                   0.86                       0.54                                 0.12                                  
  **Female donor to male recipient**                                            No             23 (17-31)                 15 (10-22)                  61 (53-69)                  65 (57-73)                 30 (23-37)                           8 (4-13)                              44 (36-52)
  Yes                                                                           25 (10-43)     19 (13-26)                 56 (37-75)                  61 (43-78)                  39 (22-55)                 19 (8-35)                            44 (26-60)                            
  *P*-value                                                                     0.91           0.35                       0.51                        0.39                        0.21                       **0.04**                             0.81                                  
  **Cytogenetic risk**                                                          Intermediate   18 (12-25)                 16 (11-23)                  65 (57-73)                  69 (61-77)                 30 (23-37)                           11 (8-17)                             45 (36-53)
  Adverse                                                                       44 (27-60)     15 (10-21)                 41 (24-58)                  43 (27-60)                  37 (22-51)                 2 (1-11)                             40 (24-56)                            
  *P*-value                                                                     **0.003**      0.64                       **0.02**                    **0.004**                   0.27                       0.09                                 0.77                                  
  **In-vivo T-cell depletion**                                                  No             24 (11-40)                 25 (10-44)                  51 (32-71)                  49 (30-69)                 38 (22-54)                           6 (1-17)                              64 (40-80)
  Yes                                                                           23 (17-30)     15 (4-32)                  62 (54-70)                  67 (59-75)                  30 (23-37)                 10 (6-16)                            40 (32-48)                            
  *P*-value                                                                     0.53           0.27                       0.16                        **0.04**                    0.38                       0.39                                 **0.01**                              
  **Donor CMV serostatus**                                                      Negative       22 (15-30)                 13 (7-20)                   65 (56-74)                  70 (61-79)                 24 (17-32)                           8 (4-13)                              44 (35-53)
  Positive                                                                      27 (16-40)     22 (15-30)                 50 (37-64)                  51 (37-65)                  44 (31-56)                 12 (6-22)                            44 (30-57)                            
  *P*-value                                                                     0.46           0.31                       0.16                        0.06                        **0.005**                  0.29                                 0.87                                  
  **TBI-based conditioning**                                                    No             21 (14-28)                 16 (10-23)                  63 (54-71)                  67 (59-76)                 31 (24-39)                           11 (6-17)                             41 (32-49)
  Yes                                                                           30 (18-43)     16 (10-23)                 54 (39-68)                  55 (40-70)                  30 (19-42)                 7 (2-15)                             53 (37-67)                            
  *P*-value                                                                     0.08           0.63                       **0.04**                    **0.04**                    0.65                       0.40                                 0.31                                  

Abbreviations: RI -- relapse incidence; NRM -- non-relapse mortality; LFS - leukemia-free survival; OS-overall survival; aGVHD -- acute graft-versus-host disease; cGVHD -- chronic graft-versus-host disease; CI -- confidence interval; CR1 -- first complete remission; CMV -- cytomegalovirus; TBI -- total body irradiation

###### Multivariate analyses

                                                                                  *P*-value   Hazard ratio   95% CI   
  -------------------------- ---------------------------------------------------- ----------- -------------- -------- ------
  **acute GVHD II-IV**       CD3 \>347 × 10\^6 /kg in vivo T-cell depletion TBI   .005        2.10           1.25     3.55
  .1                         .43                                                  .15         1.18                    
  .16                        .51                                                  .20         1.30                    
  **acute GVHD III-IV**      CD3 \>347 × 10\^6 /kg                                .006        3.60           1.45     8.96
  CD34 \>8.25 × 10\^6 /kg    .036                                                 2.65        1.07           6.57     
  adverse cytogenetic risk   .091                                                 .18         .02            1.32     
  **chronic GVHD**           in vivo T-cell depletion                             .002        .43            .25      .73
  **LFS**                    CR1 to allo-SCT \>median                             .01         .54            .34      .86
  adverse cytogenetic risk   .022                                                 1.80        1.09           2.97     
  **OS**                     CR1 to allo-SCT \>median                             .003        .47            .28      .77
                                                                                  .01         1.97           1.18     3.29
  **RI**                     CD3 \>347 × 10\^6 /kg                                .092        .50            .22      1.12
  adverse cytogenetic risk   .001                                                 2.76        1.49           5.13     
  **NRM**                    Diagnosis to CR1 \>median                            .035        2.19           1.06     4.55

Abbreviations: GVHD -- graft-versus-host disease; LFS - leukemia-free survival; OS-overall survival; RI -- relapse incidence; NRM -- non-relapse mortality; TBI -- total body irradiation; CR1 -- first complete remission; allo-SCT -- allogeneic stem cell transplantation; CI -- confidence interval

DISCUSSION {#s3}
==========

In the current study we have addressed the issue of the potential impact of PB grafts composition on the outcome of RIC allo-SCT. Although this topic has been already studied, it still raises controversy because of the lack of unequivocal conclusions coming from the studies published so far \[[@R5]--[@R13], [@R19]--[@R21]\]. The discrepancies might result from the heterogeneity of patients included. In our analysis we have focused solely on patients with AML in CR1, which is the most common indication for allo-SCT (35%) \[[@R2]--[@R3]\]. As the number of procedures performed from unrelated donors exceeded those from siblings in the recent years we decided to analyze unrelated donor allo-SCT \[[@R2]--[@R3]\]. Furthermore, in order to exclude potential bias resulting from HLA disparities, we took into consideration only fully matched (10 of 10 match) donors. We have demonstrated that high CD3+ (\>347 × 10\^6/kg) and CD34+ (\>8.25 × 10\^6 /kg) cell dose content in the grafts is an independent prognostic factor associated with higher probability of severe acute GVHD grades II-IV and III-IV for CD3+ and grades III-IV for CD34+ cell dose, respectively. At the same time, we did not observe beneficial effect of such high cell doses on AML control, as it did not affect post transplantation relapse rate, and the other transplant related outcomes.

Existing data on the correlation between cell dose and transplantation outcome in the setting of RIC allo-PBSCT from unrelated donors are mainly concentrated on the impact of CD34+ cells on outcome. Our results are in accordance with a single center Swedish study that reported the association between transplantation of high doses (≥17 x10^6^ / kg) of CD34+ cells with higher incidence of acute GVHD grades II-IV \[[@R5]\]. In another single US center analysis transplantation of more than 4.2 x10^6^ CD34+ cells / kg was in turn correlated with less relapses and lower incidence of chronic GHVD \[[@R6]\]. The National Marrow Donor Program and CIBMTR were able to demonstrate in their registry based studies, in a rather heterogeneous group of patients, that transplantation of more CD34+ cells result in better outcome in terms of reducing transplant-related mortality and improving OS. The threshold values were 4.5 and 6 × 10\^6 / kg, respectively \[[@R7]--[@R8]\]. Notably, the degree of HLA match between donor and recipient varied within studied cohorts. It is conceivable that these differences in study populations may explain discrepancies of obtained results with regard to relapse incidence and GVHD. In addition, in contrast to some of other studies we did not find association between cell dose and AML relapse, which may be related to the fact that only patients in CR1 were included in our study \[[@R6], [@R9]--[@R10]\]. It is reasonable to believe that the scenario may be different in patients with advanced disease stages. Indeed, it was previously shown that only patients with advanced disease status at transplantation (RIC from siblings) may benefit from infusion of high doses of CD34+ cells \[[@R9]--[@R10]\]. Similarly, we have not observed beneficial effect of higher CD34+ doses on NRM, LFS and OS in contrast to several previous publications \[[@R7]--[@R8], [@R10]\].

The potential impact of CD34+ cell dose on GVHD incidence, with similar to our threshold levels, was also demonstrated in the MAC allo-SCT setting from sibling donors. In the study by Przepiorka et al. transplantation of more than 8.2×10\^6 CD34+/kg was associated with increased risk of acute GVHD II-IV \[[@R14]\]. Zaucha et al. reported that exceeding of 8 × 10^6^ CD34+/kg may lead to increased risk of chronic GVHD \[[@R15]\]. The same was found by Mohty and co-workers with similar CD34+ cutoff point of 8.3 x10^6^/kg \[[@R16]\]. Also Urbano-Ispizua and colleagues were able to prove, using CD34+ positively selected transplantations model (which may allow to exclude the influence of CD3+), that high number of infused CD34+ cells might have a detrimental effect on NRM mainly due to higher incidence of acute and chronic GVHD \[[@R17]\]. The practical clinical message of our findings is to suggest not to exceed 8.3 × 10\^6 of CD34+ cells per kg in AML CR1 patients undergoing RIC allo-SCT from unrelated donors in order to try to avoid severe acute GVHD without impairing the other outcomes. This cell dose threshold nicely correlates with the values established in the previously published studies in patients undergoing myeloablative allo-SCT \[[@R14]--[@R17]\]. This cell dose threshold stands also in accordance with the RIC reports, we already discussed above, indicating better outcome with threshold values of at least 4.2-6.0 × 10^6^/kg \[[@R6]--[@R8]\]. It should be also noted, that in the first and only randomized trial looking at CD34 dose and outcome in an autologous setting higher stem cell dose (10-15 × 10^6^/kg *vs*. standard 4-6 × 10^6^/kg) did not yield a difference in post-transplant symptom burden or engraftment time \[[@R18]\].

The role of CD3+ cell counts is even less-well characterized. Baron et al. previously reported that high numbers of infused CD3+, CD4+, CD8+ and CD34+ cells in the setting of non-myeloablative (fludarabine and TBI 2 Gy) allo-SCT were associated with higher levels of day 28 donor T-cell chimerism \[[@R13]\]. In contrast, we did not reveal any relationship between CD3+ or CD34+ cell dose and engraftment rate, kinetics of engraftment nor the probability of achieving full donor chimerism. The disparity may be related to differences in the conditioning regimens used in the two studies, reasoning that the impact of cell dose on engraftment may be more important in non-myeloablative conditioning. Additional data regarding the possible role of T cell content in RIC allo-SCT setting come from studies which included both related and unrelated donors and were also more heterogeneous than our study group in terms of disease types and disease stages. Recent analysis by Reshef et al. indicates that higher CD8+ cell doses may be associated with lower RI and improved LFS and OS without increasing NRM and GVHD risk \[[@R19]\]. Cao at al. showed correlation between CD8+ graft content improvement of LFS in non-myeloablative setting \[[@R20]\]. Mohty et al. showed in turn that CD8+ cell dose affect development of acute GVHD \[[@R21]\]. We did not observe an influence of high CD3+ doses on AML relapse and survival but only its impact on the risk of severe acute GVHD, which partially correlates with the data by Mohty et al. Due to the limitations related to the retrospective nature of the study we were unable to analyze any CD3+ cell subsets on the outcome. As T cells are the major effector cells taking role in GVHD pathogenesis, it seems not surprising that the number of T-cells in the graft was found to be associated with acute GVHD risk. Indeed, removing T-cells from the graft by *ex vivo* T-cell depletion or *in vivo* T-cell depletion using ATG reduce the incidence of GVHD in a dose dependent way \[[@R22]\]. We have established the threshold value of \>347 × 10\^6 CD3+ cells/kg based on our patient population. However, we are aware that to recommend a certain CD3+ cell dose value to be infused in the grafts in general is more complex because of the presence of many confounding factors which may exist and modulate T cell responses including type of immunosuppressive regimen, ATG brand, dosage and timing and more \[[@R22]--[@R23]\]. In-vivo T-cell depletion, which is the common practice within European centers, was used in 82% of our transplants. In the vast majority of cases (104 patients, 68%), thymoglobulin at the dose 4-6 mg/kg was administrated. Such dose range was previously shown not to increase the incidence of relapses and decrease the incidence of acute and chronic GVHD \[[@R24]--[@R26]\]. Type of immunosuppressive regimen (CSA/MTX and CSA/MMF) was equally distributed between patients receiving the highest and lower doses of CD3+ and CD34+ cells. Due to limitations of retrospective analysis we were unable to check other post-transplant interventions which could also impact the outcome like for instance target cyclosporine levels used in particular centers. Only 18 patients received donor lymphocyte infusions which were equally distributed between the two groups receiving the highest and lower doses of CD3+ and CD34+ cells, respectively.

In conclusion, our results suggest that the incidence of severe acute GVHD post RIC allo-SCT, still a major cause of morbidity and mortality, is associated with the composition of the PBSC grafts, specifically it positively correlates with higher numbers of infused CD3+ and CD34+ cells. As graft composition can be manipulated, e.g. by cryopreservation of a part of stem cell product, careful assessing the CD3+ and CD34+ graft content and tailoring the cell dose infused may help in reducing the risk of severe acute GVHD risk and improving transplantation outcome. Prospective randomized trials looking at the impact of cell dose on outcomes should be conducted to avoid potential limitations coming from retrospective analyses published so far.

MATERIALS AND METHODS {#s4}
=====================

Study design and data retrieval {#s4_1}
-------------------------------

Data for this study were provided and approved by the Acute Leukemia Working Party of the EBMT group registry. Audits are routinely performed to determine the accuracy of the data. Since 1990, patients provide informed consent authorizing the use of their personal information for research purposes.

Criteria of selection {#s4_2}
---------------------

Inclusion criteria were as follows: 1) patients with *de novo* AML in CR1, 2) age ≥18 years, 3) allo-SCT performed from matched unrelated donor, 4) mandatory 10 out of 10 loci compatibility for HLA-A, -B, -C, -DRB1, and -DQB1, 5) peripheral blood as a source of stem cells, 6) reduced intensity conditioning regimen defined according to EBMT guidelines (Minimum Essential Data (MED-A) form) and published working definitions (i.e. based on busulfan at the total dose ≤ 8 mg/kg oral or intravenous equivalent (or other cytotoxic drugs) or on total body irradiation (TBI) ≤ 6 Gy) \[[@R27],[@R28]\], 7) transplant period between January 2000 and December 2012, 7) known information on the transplanted cell dose (CD34+ and CD3+). Use of *in vivo* antithymocyte globulin (ATG) or Campath was allowed, whereas *ex vivo* T-cell depletion was an exclusion criterion.

Patients and allo-PBSCT procedure {#s4_3}
---------------------------------

A total of 203 individuals met the selection criteria. Their median age was 58 (range, 21-73) and 57% of them were male. One hundred forty two (70%) of the patients had intermediate and 42 (21%) unfavorable AML cytogenetic features, while only four (2%) of them were categorized as having favorable cytogenetics. The karyotype risk category was unknown for 15 (7%) of the patients. Median donor age was 34 (19-61) years. The preparative regimen was based on chemotherapy in 143 (70%) of transplants whereas in 60 (30%) TBI was applied. In-vivo T-cell depletion was used in 166 (82%) of the transplants. Patients received GVHD prophylaxis mostly with cyclosporine and methotrexate (n=129, 64%) or with cyclosporine and mycophenolate mofetil (n=69, 34%). The CD34+ and CD3+ cell counts were determined by the cell processing laboratories at participating transplantation centers and reported to the EBMT registry. The transplanted doses were calculated based on actual body weight of the patient. The body mass index (BMI) and Karnofsky performance status did not statistically differ between patients transplanted with the highest *vs*. lower CD34+ (p=0.37 and p=0.2, respectively) and also CD3+ doses (p=0.1 and p=0.44, respectively). The median transplanted CD34(+) dose was 6.53 × 10\^6 cells per kg (range, 1.34-41.3; interquartile range, 5.0-8.25). The median CD3(+) dose was 250 × 10\^6 cells per kg (range, 50-885; interquartile range, 175.4-347). The median follow-up was 22 months (3-105). Detailed patient and transplant characteristics are summarized in (Table [1](#T1){ref-type="table"}).

Statistical analysis {#s4_4}
--------------------

Leukemia-free survival (LFS) was defined as survival with no evidence of relapse. Non-relapse mortality (NRM) was defined as probability of death while in CR. Acute and chronic GVHD were assessed and graded according to standard criteria \[[@R29]--[@R30]\]. Engraftment was defined as achieving granulocyte recovery in peripheral blood higher than 500 cells /μl for three consecutive days. The following patient\'s or graft characteristics were analyzed for their potential prognostic value in univariate analyzes: patient/donor age, sex-matching including female donor to male recipient, patient/donor CMV serology, time interval from diagnosis to CR1 and from CR1 to allo-SCT, cytogenetics risk group, use of *in vivo* T cell depletion, use of TBI in the conditioning regimen, infused dose of CD3 and CD34 cells. Continuous variables (CD34+ and CD3+ cell counts) were categorised as follows: each variable was first divided into four categories according to the quartiles. If the relative event rates (ratio of the observed number of events to the expected number of events in a category, assuming no variation across categories) in two or more adjacent categories (and the mean times-to-event) were not substantially different, these categories were grouped. If a linear trend was observed in the relative event rates, the variable was used as a continuous factor. Otherwise, the median was used as a cut-off point. Cumulative incidence functions (CIF) were used to estimate the probabilities for acute and chronic GVHD, neutrophil recovery, RI and NRM in a competing risks setting, since death and relapse are competing together \[[@R31]\]. Probabilities of overall survival (OS) and LFS were calculated using the Kaplan-Meier estimates \[[@R32]\]. Univariate analyses were performed using log-rank test for LFS and OS, Gray\'s test for CIF. All prognostic factors with a p-value lower than 0.10 on any of the endpoints in the univariate analysis were introduced in a multivariate analysis, then a stepwise backward procedure was used with a cut-off significance level of 0.05 for deleting factors in the model. Multivariate analyses were performed using Cox proportional-hazard model for OS and LFS, Fine-Gray model for other outcomes \[[@R33]--[@R34]\]. All tests were two-sided with type I error rate fixed at 0.05. Statistical analyses were performed with the SPSS 19 (SPSS Inc./IBM, Armonk, NY, USA) and R 3.1.2 (R Development Core Team, Vienna, Austria) software packages.

The authors thank all participating EBMT centers for providing data for this analysis.
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